We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+8.01%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$20.1B
AUM Growth
+$3.5B
Cap. Flow
+$2.5B
Cap. Flow %
12.41%
Top 10 Hldgs %
33.13%
Holding
257
New
120
Increased
40
Reduced
39
Closed
20

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$546M
2
WTW icon
Willis Towers Watson
WTW
+$471M
3
MA icon
Mastercard
MA
+$344M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$240M
5
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
+$238M

Top Sells

Rank Stock Value
1
TIF
Tiffany & Co.
TIF
+$301M
2
NYT icon
New York Times
NYT
+$209M
3
V icon
Visa
V
+$194M
4
ELV icon
Elevance Health
ELV
+$145M
5
ABBV icon
AbbVie
ABBV
+$123M

Sector Composition

Rank Sector Weight
1 Healthcare 35.71%
2 Technology 14.95%
3 Financials 13.65%
4 Communication Services 11.15%
5 Industrials 7.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMA
76
ImageneBio Inc
IMA
$62.5M
$38.1M 0.19%
+112,459
New +$38.5M
RP
77
DELISTED
RealPage, Inc.
RP
$36.2M 0.18%
+415,000
New +$36.1M
QTRX icon
78
Quanterix
QTRX
$141M
$35.1M 0.17%
+600,000
New +$40.6M
CHNG
79
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$32.1M 0.16%
+1,453,600
New +$33.6M
NVAX icon
80
Novavax
NVAX
$1.47B
$31.7M 0.16%
175,000
-100,000
-36% -$19.9M
COHR
81
DELISTED
Coherent Inc
COHR
$31.6M 0.16%
+125,000
New +$27.8M
PLRX icon
82
Pliant Therapeutics
PLRX
$71.8M
$30.1M 0.15%
764,262
– –
BIIB icon
83
Biogen
BIIB
$32B
$28.8M 0.14%
103,000
– –
IONS icon
84
Ionis Pharmaceuticals
IONS
$9.93B
$28.3M 0.14%
630,500
-119,500
-16% -$6.66M
KVSC
85
DELISTED
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
$28.1M 0.14%
+2,809,000
New +$27.8M
VAR
86
DELISTED
Varian Medical Systems, Inc.
VAR
$26.5M 0.13%
+150,000
New +$26.4M
NUVB icon
87
Nuvation Bio
NUVB
$2.43B
$26.1M 0.13%
2,500,000
– –
SAGE
88
DELISTED
Sage Therapeutics
SAGE
$25.8M 0.13%
345,000
-705,000
-67% -$57.8M
TGTX icon
89
TG Therapeutics
TGTX
$8.31B
$24.1M 0.12%
500,000
+400,000
+400% +$19.2M
CLVR
90
DELISTED
Clever Leaves Holdings Inc. Common Shares
CLVR
$23.4M 0.12%
75,936
-6,667
-8% -$2.43M
CNST
91
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$23.4M 0.12%
1,000,000
+250,000
+33% +$7.57M
ORTX
92
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$23.3M 0.12%
+321,543
New +$22.8M
NXDR
93
Nextdoor Holdings
NXDR
$925M
$22.7M 0.11%
+2,250,000
New +$22.5M
SRPT icon
94
Sarepta Therapeutics
SRPT
$1.98B
$22.4M 0.11%
300,000
-300,000
-50% -$27.7M
REVHU
95
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Units
REVHU
$20.1M 0.1%
+2,000,000
New +$20.1M
DCRCU
96
DELISTED
Decarbonization Plus Acquisition Corporation III Unit
DCRCU
$19.9M 0.1%
+2,000,000
New +$19.9M
ZYME icon
97
Zymeworks
ZYME
$2.05B
$18.9M 0.09%
600,000
-150,000
-20% -$6.1M
FPRX
98
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$18.9M 0.09%
501,618
+101,618
+25% +$2.53M
FVIV.U
99
DELISTED
Fortress Value Acquisition Corp. IV Units, each consisting of one share of Class A common stock and one-eighth of one redeemable Warrant
FVIV.U
$17.3M 0.09%
+1,750,000
New +$17.5M
RC
100
Ready Capital
RC
$311M
$16.8M 0.08%
1,250,226
-100,000
-7% -$1.3M
2 3
4
5 6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2021 Portfolio in Review

As of Q1 2021, Thomas Steyer held 257 positions worth $20.1B, up 21% from $16.6B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Thomas Steyer deployed $2.5B of net new capital in Q1 2021, opening 120 new positions and adding to 40 existing holdings. Its largest new stake was Mastercard: 985,920 shares worth $351M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was New York Times, an estimated $209M trimmed.

  • Thomas Steyer's largest Q1 2021 buy was Mastercard: 985,920 shares worth $351M.
  • Thomas Steyer added most to Alexion Pharmaceuticals in Q1 2021, an estimated $546M increase.
  • Thomas Steyer's biggest Q1 2021 reduction was New York Times, cutting an estimated $209M.
  • Thomas Steyer fully exited Tiffany & Co. in Q1 2021, selling an estimated $301M.
  • Thomas Steyer's ten largest holdings make up 33% of its $20.1B portfolio in Q1 2021.
  • Thomas Steyer opened 120 new positions and closed 20 in Q1 2021.
  • Thomas Steyer's portfolio value rose 21% quarter-over-quarter to $20.1B.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.